Innovative Therapeutics in Oncology and Neuroscience
+
Adagrasib ± Cetuximab
Compelling Early Efficacy in Pre-Treated Patients with Colorectal Cancer
Late-stage
Prognosis on SoC in CRC with KRAS G12C Mutations
Population
Historical Efficacy Outcomes in 3L+
Regorafenib¹ or Trifluridine/Tipiracil2.3:
KRAS-agnostic
-
KRAS-mutant
ORR: 1-2%
mPFS: 1.9-2.0 months
MOS: 6.4-8.0 months
Trifluridine/Tipiracil³:
KRAS-mut mOS: 6.5 months
Adagrasib Monotherapy (KRYSTAL-1 study)4
Efficacy Profile Summary (n=43)
•
Confirmed ORR was 19% (8/43);
DCR was 86% (37/43)5
Tumor shrinkage of any magnitude
occurred in 79% of patients
Median DOR was 4.3 months
Safety Profile Summary (n=44)
•
No Grade 5 TRAES
•
No TRAES led to
discontinuation
Patient outcomes in CRC have historically been poor and
progressively worse in later lines of therapy
•
KRAS-mutant CRC patients tend to have worse outcomes
than the broader CRC patient population
Adagrasib + Cetuximab (KRYSTAL-1 study) 4
Efficacy Profile Summary (n=28)
Confirmed ORR was 46%
(13/28); DCR was 100% (28/28)6
Tumor shrinkage of any
magnitude occurred in 93% of
patients
•
Median DOR was 7.6 months
Safety Profile Summary (n=32)
•
No Grade 5 TRAES
No TRAES led to
discontinuation of adagrasib
16% of TRAEs led to
discontinuation of cetuximab
34
Sources: Mirati corporate presentation, September 2022; ESMO 2022.
Notes: (1) Obermannová R, et al. Ann Oncol. 2016;27(11):2082-2090; (2) Grothey A, et al. Lancet. 2013;381(9863):303-312; (3) Mayer RJ, et al. N Engl J Med. 2015;372(20):1909-1919.; Van Cutsem E, et al. Eur J Cancer. 2018;90:63-72; (4)
Presented at the European Society for Medical Oncology (ESMO) Congress, September 2022, data as of June 16, 2022; (5) Response outcome per investigator assessment with a median follow-up of 20.1 months; (6) Response outcome per
investigator assessment with a median follow-up of 17.5 months.
Clinical Data -
OncologyView entire presentation